Navigation Links
Karo Bio Announces Sucessfule Phase II Results of KB2115

HUDDINGE, Sweden,11-Jun-2007 / Karo Bio (STO:KARO) successful KB2115 Phase II study meets primary objectives. The 12 week proof of concept phase II study with KB2115 in patients with dyslipidemia has been successfully completed. KB2115 is efficacious in LDL lowering and safe with respect to a broad range of parameters reflecting effects on heart, bone, muscle and thyroid function.

The thyroid hormone receptor (TR) is a key regulator of metabolic pathways and holds the promise of a new target for the treatment of dyslipidemia. KB2115 is an innovative and first in class liver selective agonist for the TR. Unlike the natural thyroid hormones, KB2115 is a liver selective TR agonist that can induce pharmacological effects in the liver, while a normal thyroid state is preserved in the rest of the body.

The completed 12 week, placebo controlled, double blind, randomised, clinical phase II study in 99 patients with high cholesterol levels was designed to explore whether a clinically relevant LDL-cholesterol lowering effect can be achieved without affecting the heart, bone, muscle and thyroid function.

The study demonstrated that a pronounced and clinically relevant lowering of LDL cholesterol can be obtained while preserving the thyroid homeostasis outside the liver and biomarkers for heart, bone, muscle and other organs were kept at normal levels. The mild increase in liver enzymes that was picked up in the previous 2-week phase I trial, was observed in this study as well, however, it seems to be a transient and benign effect. In addition to the positive result regarding efficacy and safety it was also shown that the enteric coating of KB2115 was effective in protecting the compound from chemical modification in the stomach.Thereby, a safety concern for longer exposure in man is removed.

The specific results from the KB2115 phase II study will be presented at upcoming international conferences dur ing the year. The phase II program for KB2115 will continue with additional studies both in combination with statins, as well as in defined patient groups, to prepare for the phase III program.

"This is a break through for Karo Bio" says Per Olof Wallström, President of Karo Bio. "The major concerns around KB2115 have been adequately addressed and successfully resolved. The results are impressive and clear, KB2115 induces a significant lowering of LDL and the compound appears to be safe in a longer study. We strongly believe that KB2115 will be beneficial in the future treatment of dyslipidemia and that the compound may well be a candidate for use in a broader patient population".

KARO BIO AB

For further information, please contact: Per Olof Wallström, President & Chief Executive Officer Telephone: +46 8 608 60 20

Per Otteskog, Senior Vice President Telephone: +46 8 608 60 18

Facts about Karo Bio Karo Bio is a drug discovery and development company specializing in nuclear receptors for the development of novel pharmaceuticals with focus on metabolic diseases. Karo Bio has three clinical and four preclinical projects.

The company has expanded from being a drug discovery company by adding in-house preclinical and clinical development resources and competence for development of drugs to treat metabolic diseases. The company has a strong project portfolio with innovative molecules that primarily targets diseases such as diabetes, atherosclerosis and dislipidemia. In all of these areas there are significant market opportunities and a growing need for new pharmaceuticals with new mechanisms of action.

In addition to the proprietary projects Karo Bio has two strategic collaborations with international pharmaceutical companies and one biotech collaboration for development of innovative therapies for the treatment of common diseases.

Karo Bio is listed on the Stockholm Stock Exchange since 1998 (Reuters: K ARO.ST).

This press release is also available online at: www.karobio.com and www.waymaker.net.


'"/>




Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016  The blood testing market ... dollars, according to Kalorama Information and The Freedonia Group ... and nucleic acid testing.  The healthcare research firm said ... in developing blood collection stations and in improving testing ... Kalorama Information,s report, Blood Testing Market in ...
(Date:4/28/2016)... , April 28, 2016 Dr. ... and Ste phen ... ArisGlobal®, a leading provider of cloud-based software solutions for life ... Pharmacovigilance team to bring a wealth of insight to a growing ... pharmacovigilance knowledge. George Phillips joined ArisGlobal in ...
(Date:4/28/2016)... 28, 2016  ValGenesis, Inc., the market ... (VLMS) today announced that a prominent world ... of chronic kidney failure has selected ValGenesis ... corporate validation process. The global medical device ... to manage their validation processes electronically. Upon ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... ... flexibility in repaying their loans, more information about their loan terms and accounts, ... outstanding student loan debt, including federal and private loans, has reached $1.3 trillion, ...
(Date:4/29/2016)... ... April 29, 2016 , ... A ... born with severe congenital diaphragmatic hernia have better survival rates if surgery is ... hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal organs ...
(Date:4/29/2016)... Kansas City, Missouri (PRWEB) , ... April 29, 2016 , ... ... Unlike traditional crutches which put pressure on the armpits, the M+D Crutch evenly distributes ... less strain on their wrists and hands when using the crutches than with other ...
(Date:4/29/2016)... ... 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although only about 1 ... skin cancer deaths. More than 10,000 people are expected to die of melanoma this year. ... is the one of the most commonly diagnosed cancers in young women. A recent breakthrough ...
(Date:4/29/2016)... ... ... Reltok Nasal Products proudly announces that Boston Medical Products, Inc., a leading ... specialty, has added the KOTLER NASAL AIRWAY™ to its diverse product line. , A ... safety device secured by nasal surgeons onto the floor of the nasal passages, at ...
Breaking Medicine News(10 mins):